 |
인쇄하기
취소
|
Caspase inhibitor in Phase IIb clinical trial
LG Life Sciences, Ltd. (LGLS) says that its US partner Gilead Sciences is conducting a Phase IIb clinical trial in 240 patients chronically infected with the hepatitis C virus to evaluate caspase inhibitors, which was independently developed by LGLS.
In November 2007, both companies entered into an exclusive license agreement focused on the development of caspase inhibitors for the treatment...
In November 2007, both companies entered into an exclusive license agreement focused on the development of caspase inhibitors for the treatment...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.